Osteoplex Liquid
NDC Package 43857-0555-1
Package Information
Osteoplex (equisetum hyemale, magnesia muriatica, ascorbicum acidum, manganum muriaticum, symphytum officinale, medulla ossis suis, calcarea fluorica, calcarea phosphorica, silicea, parathyroid gland (suis), ligament (suis)) liquids is for temporary relief of pain in lower part of the back with burning, chronic lower back pain, soreness in the sacroiliac area, pain in the joints & bones. This formulation utilizes a liquid delivery system. Marketed by Bioactive Nutritional, Inc., this product is identified by NDC 43857-0555.
Identification & Billing
Clinical Specifications
- ASCORBIC ACID 6 [hp_X]/mL
- CALCIUM FLUORIDE 12 [hp_X]/mL
- COMFREY ROOT 6 [hp_X]/mL
- EQUISETUM HYEMALE WHOLE 3 [hp_X]/mL
- MAGNESIUM CHLORIDE 3 [hp_X]/mL
- MANGANESE CHLORIDE 6 [hp_X]/mL
- SILICON DIOXIDE 12 [hp_X]/mL
- SUS SCROFA BONE MARROW 8 [hp_X]/mL
- SUS SCROFA LIGAMENT 30 [hp_C]/mL
- SUS SCROFA PARATHYROID GLAND 8 [hp_C]/mL
- TRIBASIC CALCIUM PHOSPHATE 12 [hp_X]/mL
- Ascorbic Acid - [CS]
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Magnetic Resonance Contrast Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Paramagnetic Contrast Agent - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
- Vitamin C - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 43857 - Bioactive Nutritional, Inc.
- 43857-0555 - Osteoplex
- 43857-0555-1 - 30 mL in 1 BOTTLE, DROPPER
- 43857-0555 - Osteoplex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43857-0555-1 identifies a specific commercial package of 30 ml in 1 bottle, dropper of Osteoplex, a human over the counter drug labeled by Bioactive Nutritional, Inc.. This liquid is formulated for oral use and contains ascorbic acid; calcium fluoride; comfrey root; equisetum hyemale whole; magnesium chloride; manganese chloride; silicon dioxide; sus scrofa bone marrow; sus scrofa ligament; sus scrofa parathyroid gland; tribasic calcium phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bioactive Nutritional, Inc. on July 15, 2020. The current certification is valid through December 31, 2027.
How is this Bioactive Nutritional, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43857055501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.